Moneycontrol
Oct 17, 2016 01:19 PM IST IST | Source: Moneycontrol.com

Marksans Pharma soars 4% on USFDA approval for Paricalcitol drug

Marksans Pharma shares gained 4 percent intraday Monday after the company has received approval from the US health regulator for Paricalcitol capsules.


Moneycontrol Bureau


Marksans Pharma shares gained 4 percent intraday Monday after the company has received approval from the US health regulator for Paricalcitol capsules.


Paricalcitol oral capsules are used to treat or prevent overactive parathyroid gland - hyperparathyroidism. It is also a man-made form of vitamin D.


It is the second drug approval from the US Food and Drug Administration since September.


On September 26, the USFDA granted approval for abbreviated new drug application for Loratadine liquid filled capsules 10 mg. It is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching and other allergy symptoms.


Both drugs were filed from its Goa plant.

At 12:47 hours IST, the scrip of Marksans Pharma was quoting at Rs 53.10, up Rs 1.05, or 2.02 percent on the BSE.

Posted by Sunil Shankar Matkar

Sections
Follow us on
Available On